Vitiligo

Vitiligo: A Nutrition and Natural-Health Reference

Definition and Clinical Presentation

Vitiligo is an acquired chronic pigmentary disorder affecting the melanocytes, mainly in the skin and mucosae. More specifically, it is an acquired pigmentary skin disorder caused by the absence of pigmentary cells from the epidermis that results in white macules and patches on the body. The clinically characteristic symptoms are pale or milk-white macules or patches due to the selective destruction of melanocytes; they occur on the skin in different parts of the body and sometimes also on the mucous membranes.

It can be classified into two primary forms: segmental and non‐segmental vitiligo, with the latter being the most common manifestation. The prominent clinical feature of vitiligo is the presence of well-defined white patches on the skin or mucous membranes caused by a defect in melanocytes in the skin or hair, or both. Segmental vitiligo is characterized by unilateral, localized distribution of lesions, more often with rapid onset and stabilization with early hair follicle involvement. Nonsegmental vitiligo is characterized by bilateral distribution of lesions on the body, more frequently with progressive onset with multiple flare-ups, later hair follicle involvement, and an unpredictable course.

The condition can appear at any age, from childhood to adulthood, but peak incidence is reported in the second and third decades; its prevalence is approximately 0.1% to 2% of people, including adults and children worldwide, and it affects all races. Half of all patients develop the disease before 20 years of age. Onset at an advanced age occurs but is unusual and should raise concerns about associated diseases such as thyroid dysfunction, rheumatoid arthritis, diabetes mellitus, and alopecia areata.

Vitiligo may also involve the hair follicles, and in different extensions of the skin it may accompany systemic manifestations such as sensorineural deafness, uveitis, and thyroiditis. Although not accompanied by disturbing senses like pruritus or pain, vitiligo might negatively affect people's self-esteem and even cause anxiety or depression, as the disfiguring spots hamper social interaction.

Epidemiology

The prevalence of the disease is around 1% in the United States and in Europe, but ranges from less than 0.1% to greater than 8% worldwide. The prevalence of vitiligo is quite variable around the world, being more frequent in Africa (0.4%), Europe (0.4%), and Oceania (1.2%), than in North America (0.2%) and Asia (0.1%). A population-based multinational survey among 35,694 participants across Europe, the USA, and Japan estimated total vitiligo prevalence at 1.3%, comprising 0.6% formally diagnosed, 0.4% undiagnosed, and 0.3% showing vitiligo signs.

Large-scale genetic epidemiologic analyses indicated that in European-derived white populations, the overall frequency of vitiligo in probands' first-degree relatives was 7%, with risk at 7.8% in probands' parents and 6.1% in siblings, consistent with polygenic, multifactorial inheritance and age-dependency of vitiligo onset.

Body Systems Involved

Vitiligo is not limited to the skin surface. It is an autoimmune skin condition characterized by the loss of melanocytes, responsible for producing skin pigments that offer protection against ultraviolet radiation. Multiple organ systems are engaged in its pathology:

• Immune system: Autoreactive CD8+ T‐cells that target melanocytes and release inflammatory mediators, including interferon‐γ and interleukins 2, 6, 15, 17, and 33 among others, have been identified in vitiligo pathogenesis.
• Integumentary system (skin, mucosae, hair follicles): The disorder promotes autoimmune aggression against melanocytes, resulting in hypochromic or achromic macules and patches on the skin and mucous membranes, with possible involvement of hair follicles.
• Endocrine system: The condition is usually associated with a few autoimmune disorders, with thyroid abnormalities being the most common one.
• Eyes and ears: Vitiligo is a systemic illness that affects melanocyte function in organs other than the skin, such as the eyes and ears.
• Innate immune system: Evidence for the participation of the innate immune system in the pathogenesis of vitiligo is very consistent, with the latter being considered the link between oxidative stress and the adaptive immune response; dendritic cells, macrophages, and natural killer (NK) cells are found in the lesional and perilesional skin of patients with vitiligo, characterizing an activation of the innate immune response.

Pathophysiology

The pathogenesis of vitiligo involves a confluence of factors, including autoreactive T‐cells, altered innate and adaptive immunity, genetic predisposition, environmental influences, and melanocyte stress. Several non-exclusive theories have been proposed to explain the full spectrum of disease:

Autoimmune and Cytotoxic Mechanisms

In vitiligo, autoreactive cytotoxic T‐cells are theorized to target melanocytes and release cytokines such as interferon‐γ (IFN‐γ), thereby attracting more cytotoxic T‐cells to the skin. This cycle results in the destruction of melanocytes and the ensuing loss of pigmentation. T cells obtained from perilesional skin biopsies are significantly enriched for melanocyte antigen recognition compared with healthy skin-infiltrating T cells; these T cells can infiltrate autologous normally pigmented skin explants and efficiently kill melanocytes within this microenvironment.

Oxidative Stress

Oxidative stress triggered by elevated levels of reactive oxygen species accounts for melanocytic molecular and organelle dysfunction, a minority of melanocyte demise, and melanocyte-specific antigen exposure. Under stress, melanocytes generate reactive oxygen species (ROS) and heat shock proteins (HSP), notably HSP70i, which act as damage‐associated molecular patterns in vitiligo. In non-segmental vitiligo, early factors include activation of innate immunity, inflammasome activation, oxidative stress, and loss of melanocyte adhesion.

Genetic Predisposition

Genome-wide associated studies have identified single-nucleotide polymorphisms in a panel of susceptible loci as risk factors in melanocyte death, but vitiligo onset cannot be solely attributed to a susceptible genetic background. Genetic research revealed a multi-genetic inheritance displaying an overlap with other autoimmune disorders; some melanocyte-specific genes were also affected. Segmental vitiligo carries a different pathogenesis, with most evidence indicating a mosaic skin disorder.

Contributing and Associated Factors

Autoimmune Comorbidities

Among the various reported comorbidities of vitiligo, autoimmune thyroid diseases — such as Hashimoto's thyroiditis and Graves' disease — were highlighted as among the most commonly reported, and the association between autoimmune thyroid disease and vitiligo is well supported by epidemiological cohort studies. Vitiligo affects up to 1–2% of the population worldwide and 34% of patients have positive thyroid antibodies, making the association clinically relevant for different practitioners. The association with chronic thyroiditis is based on a common autoimmune background and excessive reactive oxygen species that destroy both melanocytes and thyrocytes (the oxidative stress hypothesis), with thyroxine and melanin as target molecules sharing a common origin: tyrosine. Common epigenetic anomalies or mutations of the Forkhead transcription factor D3 (FOXD3) have also been described.

Psychological Stress

Among the environmental factors, numerous precipitating factors have been implicated in the induction of vitiligo, such as sunburn, hormonal factors, stress, mechanical factors, and cytotoxic chemical factors. Psychological stress is frequently cited by patients as a trigger. Vitiligo is a cosmetically disfiguring condition with a substantial psychological burden; its autoimmune nature with resultant chronicity, variable responses to therapeutic modalities, and frequent recurrences have further diminished quality of life.

Physical Trauma — The Koebner Phenomenon

Burns and cuts have been documented as initiation sites for progressive depigmentation, and the Koebner phenomenon is often observed in vitiligo patients. The Koebner phenomenon has also been described in other skin diseases including vitiligo, lichen planus, viral warts, and molluscum contagiosum.

Chemical and Environmental Exposures

Chemical vitiligo is an underdiagnosed form of skin depigmentation caused by repeated chemical agent exposure, affecting both adults and children. It is also called chemical leucoderma, contact vitiligo, and/or occupational vitiligo. Most of the implicated chemical agents are derivatives of phenol and catechol, which have melanotoxic effects in individuals with genetic susceptibility. Studies using 4-tertiary butyl phenol (4-TBP) and monobenzyl ether of hydroquinone (MBEH), known triggers of vitiligo, to induce stress in human melanocytes showed that exposure can activate the unfolded protein response (UPR) and lead to increased expression of cytokines IL-6 and IL-8, which may contribute to autoimmune-mediated progression of vitiligo. Phenol-based chemicals were consistently linked to melanocyte toxicity in a systematic review of 496 studies examining exposomal factors.

Heavy Metal Exposure

A systematic review of 14 studies from 2003 to 2023 exploring the link between diet and vitiligo revealed that high levels of heavy metals, including cadmium, lead, and mercury, are significantly linked to adverse health outcomes, particularly in older adults.

Nutrients, Herbs, and Natural Ingredients

Micronutrients: Overview

Systematic reviews have compared the serum levels of vitamin B12, folic acid, folate, cobalamin, selenium, copper, zinc, iron, vitamin D, vitamin C, vitamin E, and vitamin A between vitiligo and healthy groups. Findings remain inconclusive and controversial in nature; researchers have previously explored the relationship between pigmentation, oxidative stress, and serum levels of these nutrients because autoimmune and genetic factors have historically been considered important to the pathophysiology.

Vitamin D

Reduced serum 25(OH)D levels have been largely reported in vitiligo, which is an autoimmune skin disorder characterized by the appearance of achromic macules. Since vitamin D can positively modulate immune function and stimulate melanogenesis in vitro, a possible role of sufficient vitamin D levels in promoting the stability of the disease and repigmentation process has been hypothesized in vitiligo.

Scientific evidence: In an observational study on 101 vitiligo patients followed for 6 months, those with sufficient 25(OH)D levels (30–100 ng/mL) achieved a significantly higher degree of repigmentation. The study provided novel evidence of a significant positive association of sufficient 25(OH)D levels with stability of the disease and a satisfactory repigmentation process in Caucasian adult vitiligo patients. In a prospective pediatric study, patients who were vitamin D deficient (n=14) were treated with a combination of oral vitamin D and topical tacrolimus for six months; although the study did not determine decreased serum 25(OH)D levels in children with vitiligo overall, combination treatment with oral vitamin D and topical tacrolimus was more effective in reaching repigmentation than topical tacrolimus alone.

A further randomized study determined the efficacy of intramuscular cholecalciferol with excimer laser in 26 patients with non-segmental vitiligo and low serum 25(OH)D levels (<20 ng/mL); the Vitiligo Area Scoring Index (VASI) scores showed an 83.6% improvement over the initial score in the cholecalciferol group versus 54.7% in the control group after 6 months.

Topical vitamin D analogues have also been studied. A systematic review of the utilization of topical vitamin D — specifically cholecalciferol, calcipotriol, and tacalcitol — in the treatment of vitiligo found that vitamin D plays a role in stimulating the synthesis of melanin and melanogenesis, and that the inclusion of calcipotriol or tacalcitol in narrowband UVB phototherapy has shown the potential to enhance therapeutic outcomes for vitiligo. The findings from 27 trials (n=1198) revealed that calcipotriol accounted for nearly 70% of topically used vitamin D analogues for vitiligo treatment, with tacalcitol and cholecalciferol contributing 22% and 8%, respectively. Evidence strength: observational and small prospective studies suggest an association, and adjuvant use with phototherapy shows promise; large, powered RCTs are still needed.

Vitamin B12 and Folic Acid (Folate)

In younger adults, low levels of vitamin D and deficiencies in folic acid and vitamin B12 were associated with an increased risk of vitiligo in a systematic review. Some studies showed no significant effect in combination therapy with vitamin B12 and folate, but there is also evidence of improvement in therapy with these two vitamins compared with other treatments alone. The mechanisms suggested include their role in melanin synthesis through the pteridine part of folic acid and the effect of vitamin B12 in methionine synthesis.

Scientific evidence: A meta-analysis revealed no significant differences in serum levels of vitamin B12 and copper between vitiligo patients and healthy controls. The evidence for B12 and folate as independent contributors remains mixed. Evidence strength: preliminary; individual small studies show associations, but meta-analytic data are inconclusive for serum levels, and well-controlled clinical trials of supplementation are limited.

Vitamin E

Serum concentrations of vitamin D, vitamin E, and zinc were lower in vitiligo patients according to a 2024 systematic review and meta-analysis. According to studies, vitamin E helps to treat lipid peroxidation of the skin caused by psoralen ultra-violet A (PUVA) treatment. Various antioxidants including polypodium leucotomos, ginkgo biloba, catalase/superoxide dismutase, and vitamin E have potential in vitiligo. Evidence strength: predominantly observational (lower serum levels noted); RCT data specifically on oral vitamin E supplementation as monotherapy in vitiligo are lacking.

Vitamin C

Vitamin C and its derivatives inhibit tyrosinase activity and melanin content in a dose-dependent manner. In a study with 30 patients with vitiligo, significantly lower vitamin C levels were found in patients compared with healthy controls. Vitamin C eliminates oxidative stress by oxidizing ascorbate to monodehydroascorbate and dehydroascorbate; it is also a cofactor for the enzymatic activity of prolyl hydroxylase in collagen synthesis. Evidence strength: preliminary; the inhibitory effect of vitamin C on tyrosinase means high-dose supplementation could theoretically impair melanogenesis — a paradox that warrants careful interpretation. Human supplementation trials specific to vitiligo are sparse.

Zinc

Zinc is an important micronutrient that plays a role in the normal functioning of the body and has been found to potentially aid in vitiligo treatment, although the relationship between serum levels and vitiligo is not yet fully understood. Low serum levels of zinc and copper and high selenium levels are associated with vitiligo, based on a systematic review and meta-analysis of 41 studies published between 1970 and 2022, including 3,353 vitiligo cases and 10,638 controls.

Zinc is involved in melanin synthesis, as tyrosinase — the key enzyme in melanogenesis — requires cofactor metals. Targeted supplementation including zinc, alongside vitamins D and B and probiotics, may help restore microbiota balance and modulate immune function. Evidence strength: consistent meta-analytic signal of low zinc in vitiligo patients, but causality has not been established; robust intervention trials are limited.

Copper

Low serum levels of copper are associated with vitiligo in meta-analytic data. However, a separate systematic review meta-analysis revealed no significant differences in serum levels of copper between vitiligo patients and healthy controls. Results are therefore mixed across reviews, likely due to heterogeneity in study populations. Copper's importance to melanogenesis is mechanistically clear: tyrosinase is a copper-dependent enzyme, and copper deficiency is known to cause hypopigmentation in various animal models. Evidence strength: conflicting; serum copper data are inconsistent across reviews, and the direct supplementation evidence in human vitiligo trials is insufficient to draw firm conclusions.

Selenium

Serum concentrations of vitamin D, vitamin E, and zinc were lower in vitiligo patients, while selenium and folic acid levels tended to be significantly higher in patients with vitiligo compared with healthy individuals, based on meta-analysis. The relatively elevated selenium in vitiligo may represent a compensatory antioxidant response, though this interpretation remains speculative. Evidence strength: observational meta-analytic data only; no significant human intervention trials in vitiligo specifically for selenium supplementation have been identified.

Herbs and Natural Compounds: Traditional Use vs. Scientific Evidence

Psoralea corylifolia (Bakuchi / Babchi)

Traditional use: Ayurveda has used a photosensitization approach for centuries centered on the herb Bakuchi (Psoralea corylifolia, recently reclassified as Cullen corylifolium). Its medicinal uses have been reported in British, Chinese, Indian, and American pharmacopeias in the traditional systems of Siddha, Ayurveda, and Unani. The dried mature seeds contain furocoumarins from which psoralens are derived, and these products have been utilized as a treatment of vitiligo, leprosy, and psoriasis since ancient times. Psoralea corylifolia is also widely used in Traditional Chinese Medicine and is officially listed in the Chinese Pharmacopoeia.

Scientific evidence: Psoralens, employed in modern PUVA therapy, and khellin, used in KUVA therapy, were originally derived from plant sources — Psoralea corylifolia and Ammi visnaga, respectively — used in traditional remedies for vitiligo. The psoralen-containing furocoumarins promote pigmentation, giving the plant its anti-inflammatory, anti-oxidant, and immune-modulatory properties. Due to its psoralen-containing furocoumarins, it has the potential to induce photosensitive reactions. In a PMC-published case report, adverse effects of erythema (mild to severe), phototoxic reactions, mild raise in liver transaminases, gastrointestinal disturbances, burns, itching, scaling, depigmented macules, pruritis, and giddiness are documented with the use of psoralens. Evidence strength: the active constituent (psoralen) is strongly supported — indeed, it forms the pharmacological basis of PUVA therapy — but use of the unprocessed herb without medical supervision carries documented risks.

Ginkgo biloba

Traditional use: Ginkgo biloba (also known as "maidenhair tree") is one of the oldest trees on Earth, and its leaves and seeds have been largely used in medicine for a very long time. It has a broad history of use in traditional Chinese and European herbal medicine for circulatory and cognitive support, with application to skin conditions emerging more recently.

Scientific evidence: Ginkgo biloba extract contains unique polyphenol compounds such as terpenoids (ginkgolides and bilobalides), flavonoids, and flavanol glycosides. It has anti-inflammatory, immunomodulatory, and antioxidant properties; in particular, it attenuates oxidative stress in macrophages and endothelial cells.

In one double-blind study evaluating efficacy of oral supplementation with Ginkgo biloba extracts, 52 patients were divided into two groups: 26 took G. biloba extract 40 mg three times daily and 26 took a placebo, for a 6-month treatment period. In the treatment group, a significant cessation of depigmentation was noted (p=0.006), and marked-to-complete repigmentation was observed in approximately 40% of cases. The best evidence was demonstrated in three studies with Ginkgo biloba as monotherapy, demonstrating clinical benefits or decreased inflammation. A systematic review and meta-analysis of four studies involving 91 patients found that the association of antioxidants with phototherapy — including Ginkgo biloba — was more effective than phototherapy alone (relative risk = 1.87; 95% CI: 1.10–3.17). Evidence strength: moderate preliminary evidence from small RCTs; larger multi-center trials are needed to confirm findings.

Polypodium leucotomos

Traditional use: Polypodium leucotomos (PL) is a fern species native to Central America. It was first studied in Honduras as a treatment for psoriasis. It is also known as "Calaguala"; its extracts are famous for their antioxidant and photoprotective properties and are used for the treatment of various skin diseases, such as psoriasis and atopic dermatitis.

Scientific evidence: Polypodium leucotomos primarily prevents lipid peroxidation and membrane damage in fibroblasts and keratinocytes. In addition, PL extract inhibits the oxidation of glutathione and acts as a direct ROS absorber against superoxide anion, hydroxyl, oxygen, and oxygen peroxide. It can stimulate IL-10 production and promote a shift in the cytokine profile from type 1 to type 2 T cells. It has been used in one randomized trial in combination with NB-UVB and was shown to be more effective than NB-UVB alone in inducing repigmentation of vitiligo in the head and neck. Polypodium leucotomos has been confirmed to improve repigmentation in combination with UV exposure; it reduces acute inflammation following UV irradiation via inhibition of COX-2, increased removal of cyclobutane pyrimidine dimers, and prevention of oxidative DNA damage. Reported dosages ranged from 480–720 mg/day. Evidence strength: moderate preliminary evidence from randomized controlled trials, primarily as adjuvant to phototherapy.

Khellin (from Ammi visnaga)

Traditional use: Khellin is a naturally occurring furanochromone derived from the plant Ammi visnaga. The plant has been used as a herbal medicine for different purposes — including kidney diseases and asthma — since ancient Egyptian times.

Scientific evidence: Even if the exact mechanism of action is unclear, khellin acts by stimulating melanocyte proliferation and melanogenesis. It may be administered both systemically (oral administration) or topically; the association of oral khellin with UVA is known as KUVA therapy. Because of khellin side effects, including liver dysfunction and allergic reactions, analogues of khellin with safer profiles and better efficacy have been developed and introduced in medicine for the treatment of vitiligo, where they provide good results in combination with UVA phototherapy. Documented adverse effects include khellin-related erythema, perilesional hyperpigmentation, gastrointestinal disturbances, mild raise in liver transaminases, and orthostatic complaints. Evidence strength: historical clinical use and mechanistic rationale are well-established; its active principles form the basis of KUVA photochemotherapy, but natural-form safety profile limits unsupervised use.

Cucumis melo (Melon) — Superoxide Dismutase Extract

Traditional use: Cucumis melo (melon) preparations, particularly those rich in antioxidant enzymes, have been explored in dermatological research and incorporated into some natural-health products. There is no classical traditional medicine system specifically prescribing melon enzyme extracts for vitiligo, making this an area driven primarily by modern phytochemical research.

Scientific evidence: Preliminary studies were conducted to evaluate the efficacy of a topical preparation containing Cucumis melo superoxide dismutase (SOD) and catalase in the treatment of vitiligo; in each study, the gel preparation was applied to skin lesions followed by irradiation with natural UV or artificial narrowband UVB. Even though the preparation was shown to be safe, there was no difference in repigmentation rate compared with patients treated with phototherapy alone. More interesting preliminary results were noted with a different topical formulation containing phenylalanine, Cucumis melo extract, and acetyl cysteine. Evidence strength: weak; currently limited to small preliminary trials with negative or inconclusive results for SOD/catalase-based preparations alone.

Traditional Chinese Medicine Formulations

Traditional use: Since ancient time, Traditional Chinese Medicine (TCM) has tried to treat vitiligo with different herbal products, used alone or, more often, in combination. Among the traditional Chinese products, psoralen plus UVA (PUVA therapy) had been considered the first vitiligo treatment for several decades. A particular mention is due to the "Barresi complex prescription," one of the most used formulations for vitiligo treatment in Uyghur medicine, an important part of TCM. The formulation is composed of the hot water extract of five herbs: Psoralea corylifolia, Plumbago zeylanica, Brassica juncea, Nigella glandulifera, and Vernonia anthelmintica.

Scientific evidence: The efficacy of these TCM drugs has been evaluated both in vivo and in vitro; in both study types, good repigmentation was observed, attributed to melanogenesis stimulation. Evidence strength: preliminary in vivo and in vitro data; well-designed clinical trials of individual TCM formulas in vitiligo remain limited.

Green Tea Polyphenols

Traditional use: Green tea polyphenols are extracts of green tea leaves, which have been used in medicine since ancient times. They are incorporated into modern nutraceuticals and topical formulations based on their known antioxidant and anti-inflammatory actions.

Scientific evidence: Green tea polyphenols — principally epigallocatechin gallate (EGCG) — have been studied in vitro for their capacity to neutralize reactive oxygen species and modulate immune pathways relevant to vitiligo pathogenesis. Preclinical and mechanistic literature acknowledges their potential, but specific clinical trial data for vitiligo patients remain very limited. Evidence strength: largely preclinical; human trial evidence in vitiligo is not yet established.

Dietary and Lifestyle Factors

Antioxidant Diet and Oxidative Stress Reduction

Markers of oxidative stress are found in the blood and epidermis of individuals with vitiligo, and this oxidative stress is postulated to alter melanocyte structure and activate autoimmune-mediated melanocyte destruction. Antioxidant supplementation is sometimes recommended in clinical practice as part of the treatment of vitiligo, more specifically for support in disease stabilization and as adjuvant therapy complementing phototherapy.

Antioxidant foods may have an inhibitory effect on the development of inflammatory skin disease based on the fundamental mechanisms of oxidative stress and autoimmune activation. However, a systematic review with an attempt at meta-analysis found that the trials with antioxidants had a small number of patients and a wide variety of compounds and protocols, which hindered comparison of studies; the effectiveness of antioxidants alone cannot be confirmed.

Gut Microbiome and the Gut-Skin Axis

Vitiligo is frequently associated with gut microbiota imbalances, reduced bacterial diversity, a decline in short-chain fatty acid-producing strains (e.g., Faecalibacterium, Bifidobacterium), and an increase in pro-inflammatory bacteria (e.g., Escherichia, Proteobacteria). These alterations may compromise gut barrier integrity, promote systemic inflammation, and activate autoreactive CD8+ lymphocytes.

Findings from animal studies have preliminarily suggested that modulation of gut microbiota, particularly through probiotic supplementation, significantly slowed disease progression and the depigmentation process. Depletion of gut microbiota reduced abnormal ROS accumulation and mitochondrial abnormalities in melanocytes, significantly improving depigmentation in mouse models. Dietary interventions rich in fiber, antioxidants, and anti-inflammatory compounds, alongside targeted supplementation — including vitamins D and B, zinc, and probiotics — may help restore microbiota balance and modulate immune function. Evidence strength: the gut-skin axis research is emerging and primarily based on observational and animal data; human intervention trials targeting the microbiome specifically for vitiligo are in early stages.

Phenolic Compounds in Diet

In vitiligo, a disorder of redox balance (an increase in hydrogen peroxide) enhances the process by which phenolic chemicals compete with tyrosine to produce reactive quinones. The reactive quinone acts as a covalent binding center of incomplete antigens to tyrosinase and produces new antigens. The micro-molar (non-cytotoxic) O-quinone also gains immunogenicity to induce an immune response. Compounds containing naturally occurring plant phenols or polyphenols may contribute to the progression of vitiligo through these mechanisms. This highlights a potential paradox: while many plant polyphenols carry antioxidant properties, some may also act as substrates in melanocyte stress pathways. The clinical relevance of dietary phenolic intake for individual vitiligo patients has not been established in rigorous studies.

Heavy Metal Avoidance

High levels of heavy metals, including cadmium, lead, and mercury, are significantly linked to adverse health outcomes in older adults with vitiligo, according to a systematic review. Dietary sources of heavy metals include certain seafood, contaminated water, and foods grown in polluted soil. Occupational and household chemical exposures involving phenol-based compounds are separately documented triggers, as noted in the contributing factors section.

Psychological Well-Being and Stress Management

Substantial psychological and psychosocial burdens, including depression and other mental health disorders, stigmatization, and hopelessness, further diminish quality of life in affected individuals. Vitiligo is associated with autoimmune comorbidities, especially thyroid-related disorders, as well as these psychological burdens. Psychological stress has been identified as a reported precipitating factor in disease onset and flare, and stress reduction is discussed in the clinical literature as a supportive management consideration, though the causal evidence linking specific stress-reduction interventions to measurable changes in disease activity in humans remains limited.

Sun Exposure

Controlled sun or phototherapy exposure is relevant to the natural-health discussion of vitiligo because several dietary nutrients and herbal compounds studied in relation to vitiligo — including vitamin D, folic acid, vitamin B12, and photosensitizing psoralens — have their effects modulated by UV light exposure. Vitamin D can positively modulate immune function and stimulate melanogenesis in vitro, meaning that sufficient sun exposure supporting cutaneous vitamin D synthesis could be relevant to disease stability. Vitiligo tends to occur or recur in spring and/or summer, suggesting UV exposure can both trigger and, under controlled conditions, be employed in supporting repigmentation.

Summary of Evidence Grades

• Vitamin D (adjuvant to phototherapy): Moderate preliminary evidence from small prospective and randomized studies; association with repigmentation and disease stability noted, but large RCTs remain needed.
• Ginkgo biloba: Moderate preliminary evidence from small RCTs showing cessation of depigmentation and some repigmentation as monotherapy, and adjuvant benefit with phototherapy in meta-analysis.
• Polypodium leucotomos: Moderate preliminary evidence from randomized controlled trials, primarily as phototherapy adjuvant; antioxidant and immunomodulatory mechanisms are documented.
• Psoralea corylifolia / psoralens: Strong clinical evidence for psoralen constituent as the basis of PUVA therapy; traditional use well-documented, but safety concerns with unsupervised use are significant.
• Khellin: Well-established constituent-level evidence as the basis of KUVA therapy; hepatotoxicity risk limits unprocessed herbal use.
• Zinc: Consistent meta-analytic signal of lower serum levels in vitiligo; intervention trial data limited.
• Vitamin E: Lower serum levels noted in meta-analysis; monotherapy supplementation trials in vitiligo are lacking.
• Vitamin B12 / Folate: Mixed meta-analytic results for serum levels; mechanistic rationale exists but clinical trial evidence is inconclusive.
• Gut microbiome / probiotics: Emerging field; animal and observational data are promising, but human trials targeting microbiome for vitiligo are preliminary.
• Cucumis melo SOD: Weak; small trials have not shown significant benefit over phototherapy alone.
• Green tea polyphenols: Largely preclinical; specific clinical trial data in vitiligo are not yet established.

References

• Bassiouny DA et al. Autoimmunity in vitiligo: Therapeutic implications and opportunities. PubMed, 2021.
• Pathak M et al. Vitiligo: From mechanisms of disease to treatable pathways. PMC / Skin Health and Disease, 2024.
• Rodrigues M et al. Vitiligo: An Update on Pathophysiology and Treatment Options. PubMed, 2017.
• Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo. StatPearls. NIH/NCBI Bookshelf, 2023.
• Rodrigues M et al. Update on the pathogenesis of vitiligo. PMC / Anais Brasileiros de Dermatologia, 2022.
• Spritz RA. Genetics of Vitiligo. PMC, 2017.
• Xu Z et al. The Prevalence of Vitiligo: A Meta-Analysis. PMC, 2016.
• Kulenthiran S et al. Epidemiology of Vitiligo – A Dual Population-Based Approach. PMC, 2021.
• Fukuyama M et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. PMC, 2022.
• Alikhan A et al. Vitiligo: a comprehensive overview Part I. PubMed, 2011.
• Chen J, Li S, Li C. Mechanisms of melanocyte death in vitiligo. PMC, 2021.
• van den Boorn JG et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. PubMed, 2009.
• Colucci R, Dragoni F, Moretti S. Oxidative stress and immune system in vitiligo and thyroid diseases. PubMed, 2015.
• Colucci R, Dragoni F, Moretti S. Oxidative Stress and Immune System in Vitiligo and Thyroid Diseases. PMC, 2015.
• Sandru F et al. Vitiligo and chronic autoimmune thyroiditis. PubMed, 2021.
• Sandru F et al. Vitiligo and chronic autoimmune thyroiditis. PMC, 2021.
• Luo X et al. The causal relationship between vitiligo and autoimmune thyroid diseases: A bidirectional two-sample Mendelian randomization analysis. PMC, 2024.
• Iraji F et al. Serum vitamins and trace elements in vitiligo patients: A systematic review and meta-analysis. JEADV Clinical Practice, 2024.
• Bahadur A et al. Zinc, copper, and selenium levels in vitiligo: a systematic review and meta-analysis. PMC, 2024.
• Calzavara-Pinton P et al. Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. PubMed, 2019.
• Karagüzel G et al. Vitamin D status and the effects of oral vitamin D treatment in children with vitiligo: A prospective study. PubMed (Clin Nutr ESPEN), 2016.
• Maleki M et al. Vitamin D supplementation can enhance therapeutic effects of excimer laser in patients with vitiligo. PubMed, 2023.
• Karsai S et al. Using a Topical Formulation of Vitamin D for the Treatment of Vitiligo: A Systematic Review. PMC, 2023.
• Colucci R et al. Herbal Compounds for the Treatment of Vitiligo: A Review. PMC, 2018.
• Skała E et al. Therapies with Antioxidant Potential in Psoriasis, Vitiligo, and Lichen Planus. PMC, 2021.
• Colucci R et al. The Impact of Antioxidants on Vitiligo and Melasma: A Scoping Review and Meta-Analysis. PMC, 2024.
• Rodrigues M. Vitiligo: What's old, what's new. PMC, 2021.
• Eleftheriadou V et al. Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review. PMC, 2023.
• Miot HA et al. Consensus on the treatment of vitiligo – Brazilian Society of Dermatology. PMC, 2021.
• Khalid M et al. The Safety of Medicinal Plants Used in the Treatment of Vitiligo and Hypermelanosis: A Systematic Review. PMC, 2021.
• Hussain I et al. Fabrication of anti-vitiligo ointment containing Psoralea corylifolia. PMC, 2016.
• Bhilave MP et al. Clinical evaluation of the efficacy of Shvitrahara kashaya and lepa in vitiligo. PMC (Ayu), 2011.
• Bhardwaj M et al. Babchi oil-induced phytophotodermatitis mimicking burn injury. PMC, 2020.
• Sędziak A et al. Vitiligo: Diet, microbiome, and immunomodulation. Forum Dermatologicum, 2025.
• Yin J et al. Oxidative Stress and Gut Microbiome in Inflammatory Skin Diseases. Frontiers in Cell and Developmental Biology, 2022.
• Zhang Y et al. Gut microbiota dysbiosis orchestrates vitiligo-related oxidative stress through the metabolite hippuric acid. PMC, 2025.
• Rashid H et al. The Role of Nutrition, Supplements, and the Gut Microbiome in Vitiligo. Journal of Integrative Dermatology, 2024.
• Le Poole IC et al. 4-Tertiary Butyl Phenol Exposure Sensitizes Human Melanocytes to Dendritic Cell-Mediated Killing. PMC, 2006.
• Mhadhbi I et al. Role of chemical exposure in the incidence of vitiligo: a case–control study in Tunisia. PMC, 2022.
• Toosi S et al. Vitiligo inducing phenols activate the unfolded protein response in melanocytes. PMC, 2012.
• Borah G et al. Clinico-Epidemiological Profile of Vitiligo Among Patients Attending a Tertiary Care Centre of North-East India. PMC, 2024.
• Shah H et al. Vitiligo: a complex disease and a complex approach. PMC, 2014.
• Al-Hubail A et al. Correlation between autoimmune thyroid disease and vitiligo: An analytical study. PMC, 2025.
• Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. PubMed, 2009.